Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Oppenheimer analyst Matthew Biegler initiated coverage on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with an Outperform rating and announced a price target of $7. CytomX Therapeutics shares closed at $2.32 on Wednesday. See how other analysts view this stock.
- Oppenheimer analyst Leland Gershell initiated coverage on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with an Outperform rating and announced a price target of $20. Lexeo Therapeutics shares closed at $4.65 on Wednesday. See how other analysts view this stock.
- Citigroup initiated coverage on Life360, Inc. (NASDAQ:LIF) with a Buy rating and announced a price target of $90. Life360 shares closed at $76.40 on Wednesday. See how other analysts view this stock.
Considering buying CTMX stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
